Hyperbaric oxygenation accelerates prosthetic rehabilitation of lower limb amputees

Specialized Hospital for Rehabilitation and Orthopedic Prosthetics, Belgrade, Serbia.
Undersea & hyperbaric medicine: journal of the Undersea and Hyperbaric Medical Society, Inc (Impact Factor: 0.77). 05/2013; 40(3):289-97.
Source: PubMed


The purpose of the study was to assess the effects of hyperbaric oxygen (HBO2) therapy on prosthetic rehabilitation of patients with unilateral lower limb amputation. Narang's scale,the Locomotor Capabilities Index and the two-minute walk test were used to assess functional abilities of amputees on the admission and on discharge from hospital. We also kept records of some clinical parameters whose improvement enables better mobility of patients: thigh and lower leg girth, strength of amputation stump, existence of amputation stump contracture, existence of some other complications on amputation stump, blood oxygenation and pulse palpation. Our results show that hyperbaric oxygenation accelerates prosthetic rehabilitation of lower limb amputees. HBO2-treated patients were discharged from the hospital faster than the controls (hospitalized for 133.2 +/- 54.87 days vs. 158.36 +/- 53.05 days), they had improved arterial Hb saturation (97.40 +/- 3.51% vs. 94.74 +/- 3.28 %) and pulse palpability (pulse palpable in 27 vs. 18 subjects), less complications of the amputation stump (complications present in 24 vs. 30 subjects), greater healthy leg thigh girth (50.75 +/- 3.96 cm vs. 48.90 +/- 2.59 cm), stronger amputation stump (mark 3.90 +/- 0.54 vs. 3.33 +/- 0.47) and better functional abilities as measured by adapted Narang's scale (category 3.43 +/- 1.30 vs. 4.10 +/- 1.12) and locomotor capabilities index (score 38.06 +/- 10.90 vs. 33.16 +/- 8.80). These findings highlight the increasing validity of this procedure after limb amputation, which should be confirmed by further research in multicenter studies involving a larger number of respondents.

Download full-text


Available from: Dusica Djordjevic, Feb 11, 2014
1 Follower
60 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Common causes for non-healing of diabetic foot ulcers are infection and/or ischaemia. Diabetic patients are compromised hosts as far as wound healing is concerned. Diabetes mellitus is associated with a defective cellular and humoral immunity. In particular, decreased chemotaxis, decreased phagocytosis, impaired bacterial killing and abnormal lymphocytic function have been observed, resulting in a reduced inflammatory reaction and defective wound healing. The potential benefits of hyperbaric oxygen therapy (HBO) in diabetic patients with a foot ulcer are discussed. Oxygen plays an important role in the physiology of wound healing. HBO can raise tissue oxygen tensions to levels where wound healing can be expected. Hyperbaric oxygen increases also the killing ability of leucocytes, is lethal for certain anaerobic bacteria and inhibits toxin formation in other anaerobes. Multiple anecdotal reports and retrospective studies in HBO therapy in diabetic patients suggest that HBO can be an effective adjunct in the management of diabetic wounds. Prospective studies also show the beneficial effects of HBO. Because most published studies suffer from methodological problems, there is an urgent need for a collaborative, international, randomised prospective clinical trial for the application of HBO in diabetic foot lesions, as part of a multidisciplinary treatment approach, before we can recommend HBO as standard therapy in patients with foot ulcers.
    Diabetes/Metabolism Research and Reviews 09/2000; 16 Suppl 1(S1):S55-8. DOI:10.1002/1520-7560(200009/10)16:1+<::AID-DMRR132>3.0.CO;2-T · 3.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hyperbaric oxygen therapy (HBO) could be described as a short-term, high-dose oxygen inhalation and diffusion therapy, delivered systemically through airways and blood, achieved by having the patient breathing concentrated oxygen at a pressure higher than 1 absolute atmosphere. In clinical practice, monoplace or multiplace hyperbaric chambers are used to achieve this. Treatment is usually given as daily 90- to 120-min-long HBO sessions at pressures between 2.0 and 2.5 absolute atmosphere, aiming for 30–40 treatment sessions. The use of HBO as treatment of diabetic foot ulcers has been founded on weak scientific ground, although the outcomes from previous studies are in concert with the conclusions from preclinical studies and supports the theoretical framework of HBO reversing hypoxia-induced pathology. Two well-designed randomized double-blind trials have put HBO on firmer ground and may justify adjunctive HBO treatment to a selected group of patients with nonhealing diabetic foot ulcers. Some health economic studies suggest potential cost effectiveness, but these studies are limited by deficient primary clinical data and should be interpreted with caution. Several issues remain to be addressed, such as developing robust criteria to improve treatment protocols, determining which patients are likely to benefit, and when to start and stop treatment. Copyright
    Diabetes/Metabolism Research and Reviews 02/2012; 28 Suppl 1(S1):78-84. DOI:10.1002/dmrr.2256 · 3.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic foot ulcers are still extremely difficult to heal. Therefore, therapeutic options to improve healing rates are continuously being explored. Hyperbaric oxygen (HBO) has been used in addition to standard treatment of the diabetic foot for more than 20 years. Evidence suggests that HBO reduces amputation rates and increases the likelihood of healing in infected diabetic foot ulcers, in association with improved tissue oxygenation, resulting in better quality of life. Nonetheless, HBO represents an expensive modality, which is only available in few centers. Moreover, adverse events necessitate a closer investigation of its safety. Finally, it is not entirely clear which patients stand to benefit from HBO and how these should be selected. In conclusion, HBO appears promising, but more experience is needed before its broad implementation in the routine care of the diabetic foot.
    Angiology 08/2011; 63(4):302-14. DOI:10.1177/0003319711416804 · 2.97 Impact Factor
Show more